Krupa et al 2024 — Insulin resistance in MDD: pioglitazone evidence + metabolic-MDD subtype
One-paragraph summary
Peer-reviewed psychiatry review consolidating evidence for the role of insulin resistance (IR) in major depressive disorder (MDD). The review identifies a metabolic subtype of MDD distinguishable from other MDD subpopulations, characterized by atypical clinical presentation, IR, and different responsiveness to antidepressant interventions. IR is identified as a state-marker of clinical or subclinical depression and as a predictor of nonresponse to some antidepressants. Sex- and ethnicity-dependent variation in the IR-MDD relationship is noted. Mechanistically, insulin has direct impact on monoaminergic systems known to underlie MDD symptoms (serotoninergic and dopaminergic, both dysregulated in IR subjects). Several trials assessed efficacy of insulin-sensitizing drugs in MDD. The review's load-bearing therapeutic finding: more consistent evidence for pioglitazone and lifestyle intervention / physical activity in MDD, with mixed results for metformin. For the project, this is the cross-condition anchor connecting pioglitazone to depression specifically — and depression is a well-established FM comorbidity (Kerrebijn 2025 GWAS shows rg > 0.7 genetic correlation between FM and depression-related conditions). Adds evidence to the v0.3.1 §12.9 pioglitazone candidate companion arm framing, particularly for the FM-depression-overlap subset.
Claims as triples
insulin_resistance — modulates → depression[evidence: review of metabolic-MDD subtype with IR-driven monoaminergic dysregulation; confidence: emerging]pioglitazone — modulates → depression[evidence: more consistent evidence cited vs. metformin in MDD treatment trials; confidence: emerging]metformin — modulates → depression[evidence: mixed-results trial evidence in MDD; confidence: bridging]pioglitazone — bridges → fm_central_only[evidence: depression is FM comorbidity; cross-condition cure-path mechanism; confidence: bridging]insulin_resistance — bridges → fm_central_only[evidence: metabolic-MDD subtype framing extends to FM-depression-overlap subset; confidence: bridging]
Methods note
Narrative review. Synthesizes recent psychiatry literature on IR-MDD relationship, mechanism (insulin's monoaminergic effects), clinical heterogeneity (sex, ethnicity), and therapeutic implications (insulin-sensitizer trial outcomes).
Limitations
- Review-level evidence, with the strength of being peer-reviewed in Current Opinion in Psychiatry — a relatively high-impact psychiatry venue.
- Mostly MDD-focused. Translation to FM rests on the FM-depression comorbidity (well-established) and the Kerrebijn 2025 GWAS genetic correlation (rg > 0.7 with PTSD; less directly with MDD). Translation requires the additional inference that the metabolic-MDD subtype and FM-with-depression overlap share substrate.
- Mixed metformin results in MDD complicates the metformin cure-path framing — adds another negative-result counterweight alongside Abdelgaied 2026 RRMS pilot.
- No FM-specific trial of pioglitazone yet. The pioglitazone framing for FM rests on cross-condition extrapolation through this paper and Qin 2026 EAE work.
Open questions raised
- Does IR-positive FM (a subset to be identified by HbA1c, HOMA-IR, fasting glucose stratification in the biomarker-mapping cohort) respond preferentially to pioglitazone over standard antidepressants in FM-depression-overlap?
- Does the metabolic-MDD subtype overlap with the post-COVID-FM cube cell (Giménez-Orenga 2025 Ferritin + MCHC differentiator)? Both are metabolic-mediated phenotypes.
- Is there an FM-equivalent metabolic-FM subtype that responds preferentially to insulin-sensitizers? Stratified observational data would directly test this.
Triangulation notes
- Connects pioglitazone (introduced via Qin 2026 EAE work) to the FM-depression-comorbidity dimension. The v0.3.1 §12.9 pioglitazone candidate companion arm now has cross-condition support across EAE (Qin), DN (Andrei), and MDD (this paper).
- Adds discipline to the metformin framing. Krupa documents mixed metformin results in MDD trials — another data point alongside Abdelgaied 2026 negative MS pilot. Pattern consistent with the parsimonious unified read: metformin works prophylactically / in early-window but has limited efficacy in established neurodegenerative or psychiatric disease.
- Suggests stratification axis for biomarker-mapping cohort. HbA1c / HOMA-IR / fasting glucose / insulin could be added as a 15th cohort dimension for stratifying the metabolic-syndrome / metabolic-FM subset. Cheap, established assays.
Bridges
- B20 reinforced — pioglitazone / PPAR-γ-agonist class ↔ FM via cross-condition MDD evidence (depression is established FM comorbidity).
- New candidate B25 — insulin-resistance-driven metabolic subtype ↔ FM-depression-overlap. Cross-condition shared substrate framework; testable via HbA1c / HOMA-IR stratification in the biomarker-mapping cohort.